Pyxis Oncology to Focus Resources on Lead Clinical Program PYX-201

MT Newswires Live2024-12-20

Pyxis Oncology (PYXS) said late Thursday it will focus its resources on advancing its lead clinical program, PYX-201, as part of its portfolio prioritization plan.

The clinical-stage drugmaker said PYX-201 showed "significant RECIST responses" in head and neck squamous cell carcinoma as well as "additional potential in other solid tumors."

Pyxis said it will suspend further clinical investment in its second clinical program, PYX-106, to allocate resources for PYX-201. PYX-106 was in-licensed from Biosion, with Biosion retaining rights for Greater China.

The company also said its cash position is expected to fund its planned trials of PYX-201 into H2 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492348776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492348776","market":"nz","top_or_hot":-1,"title":"Pyxis Oncology to Focus Resources on Lead Clinical Program PYX-201","media":"MT Newswires Live","content":"<html><body><p> Pyxis Oncology (PYXS) said late Thursday it will focus its resources on advancing its lead clinical program, PYX-201, as part of its portfolio prioritization plan.</p><p>The clinical-stage drugmaker said PYX-201 showed \"significant RECIST responses\" in head and neck squamous cell carcinoma as well as \"additional potential in other solid tumors.\"</p><p>Pyxis said it will suspend further clinical investment in its second clinical program, PYX-106, to allocate resources for PYX-201. PYX-106 was in-licensed from Biosion, with Biosion retaining rights for Greater China.</p><p>The company also said its cash position is expected to fund its planned trials of PYX-201 into H2 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology to Focus Resources on Lead Clinical Program PYX-201</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology to Focus Resources on Lead Clinical Program PYX-201\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 06:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pyxis Oncology (PYXS) said late Thursday it will focus its resources on advancing its lead clinical program, PYX-201, as part of its portfolio prioritization plan.The clinical-stage drugmaker said PYX...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492348776","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492348776","pubTimestamp":1734645923,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pyxis Oncology  said late Thursday it will focus its resources on advancing its lead clinical program, PYX-201, as part of its portfolio prioritization plan.The clinical-stage drugmaker said PYX-201 showed \"significant RECIST responses\" in head and neck squamous cell carcinoma as well as \"additional potential in other solid tumors.\"Pyxis said it will suspend further clinical investment in its second clinical program, PYX-106, to allocate resources for PYX-201. PYX-106 was in-licensed from Biosion, with Biosion retaining rights for Greater China.The company also said its cash position is expected to fund its planned trials of PYX-201 into H2 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Pyxis Oncology将资源集中在主导临床项目PYX-201上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":1},"content_text":"Pyxis Oncology (PYXS) said late Thursday it will focus its resources on advancing its lead clinical program, PYX-201, as part of its portfolio prioritization plan.The clinical-stage drugmaker said PYX-201 showed \"significant RECIST responses\" in head and neck squamous cell carcinoma as well as \"additional potential in other solid tumors.\"Pyxis said it will suspend further clinical investment in its second clinical program, PYX-106, to allocate resources for PYX-201. PYX-106 was in-licensed from Biosion, with Biosion retaining rights for Greater China.The company also said its cash position is expected to fund its planned trials of PYX-201 into H2 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492348776"}